# Filing Detail

Form PRE 14A - Other preliminary proxy statements:
SEC Accession No. 0001731122-21-000497
Filing Date
2021-04-01
Accepted
2021-04-01 16:06:51
Documents
5
Period of Report
2021-04-01

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | PRELIMINARY INFORMATION STATEMENT | e2572_pre14a.htm | PRE 14A | 289477
2 | GRAPHIC | e2572proxy_1.jpg | GRAPHIC | 297585
3 | GRAPHIC | e2572proxy_2.jpg | GRAPHIC | 338393
4 | GRAPHIC | e2572annexa_1.jpg | GRAPHIC | 484621
5 | GRAPHIC | e2572annexa_2.jpg | GRAPHIC | 371571
| Complete submission text file | 0001731122-21-000497.txt |  | 2345206

Mailing Address 51 W 52ND STREET, 7TH FLOOR NEW YORK NY 10019-6163
Business Address 51 W 52ND STREET, 7TH FLOOR NEW YORK NY 10019-6163 800-689-3939
ANAVEX LIFE SCIENCES CORP. (Filer) CIK: 0001314052 (see all company filings)

EIN.: 208365999 | State of Incorp.: NV | Fiscal Year End: 0930
Type: PRE 14A | Act: 34 | File No.: 001-37606 | Film No.: 21798022
SIC: 8731 Services-Commercial Physical & Biological Research